Your browser doesn't support javascript.
loading
Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers.
Tanaka, Hidenori; Mukai, Junji; Kushibiki, Kenichi; Mizushima, Sayuri; Maeda, Kyoko; Fujimoto, Yuko; Sawada, Ryugo; Oda, Manabu; Okuda, Hiroshi; Yamaki, Mayumi; Hashiguchi, Shin; Kawai, Ichiro; Kawaguchi, Izumi; Masuda, Noriyuki; Matsushita, Haruhiko.
Afiliación
  • Tanaka H; Department of Respiratory Medicine, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan.
  • Mukai J; Department of Pharmacy, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan.
  • Kushibiki K; General Affairs Division, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan.
  • Mizushima S; Department of Clinical Laboratory, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan.
  • Maeda K; Department of Clinical Laboratory, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan.
  • Fujimoto Y; Department of Clinical Laboratory, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan.
  • Sawada R; Department of Surgery, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan; Infection Control Room, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan.
  • Oda M; Infection Control Room, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan.
  • Okuda H; Department of Pharmacy, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan.
  • Yamaki M; Medical Affairs Division, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan.
  • Hashiguchi S; Clinical Research Center, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan.
  • Kawai I; Clinical Research Center, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan.
  • Kawaguchi I; Department of Nursing, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan.
  • Masuda N; Department of Respiratory Medicine, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan; Clinical Research Center, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan. Electronic address: noriyuki.masuda@tokushukai.jp.
  • Matsushita H; Department of Respiratory Medicine, Izumi City General Hospital, 4-5-1 Wakecho, Izumi, Osaka 594-0073, Japan.
Vaccine ; 41(2): 365-371, 2023 01 09.
Article en En | MEDLINE | ID: mdl-36460533
PURPOSE: Administration of three doses of Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine was completed in Japan in the spring of 2022. This study aimed to evaluate the antibody responses, and kinetics of three doses of vaccine in healthcare workers (HCWs). PATIENTS AND METHODS: We conducted a longitudinal cohort study with HCWs, who had no history of COVID-19 or serologic evidence of SARS-CoV-2 infection, from a single hospital. Immunoglobulin G (IgG) titers of anti-SARS-CoV-2 spike protein (SP) and nucleocapsid protein (NP) titers were measured using an automated chemiluminescent enzyme immunoassay system. RESULTS: A total of 636 HCWs participated in the study. The anti-SP IgG titers decreased slowly after the second dose of the BNT162b2 vaccine in all participants, and robust antibody response was observed after the third dose of the vaccine. The peak anti-SP IgG titer after the third dose was approximately 4.1-fold higher than that after the first and second doses, and the rate of decrease in the anti-SP IgG titer after the third dose was significantly more gradual, than that after the second dose. After the second dose of vaccine, the antibody response was weaker in older participants than in younger participants, and in males than in females respectively, whereas the response to the third dose of vaccine did not differ significantly by sex or age. Adverse events following immunization were generally mild to moderate. CONCLUSION: The third dose of the BNT162b2 vaccine induced a significant and sustained increase in anti-SP IgG titers, and was generally safe and well-tolerated.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Observational_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Vaccine Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Observational_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Vaccine Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Países Bajos